Checkpoint Inhibitor Combination Therapy With Chemoradiation for Solid Tumors

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There has been limited progress in therapeutic options for advanced and metastatic cancers, particularly small-cell lung cancer (SCLC) and squamous cell carcinoma of the head and neck (HNSCC), with poor prognosis due to the limited efficacy of existing treatments.

Innovation Solution

Concurrent treatment of patients with advanced solid tumors using a human anti-PD-L1 antibody, optionally combined with an anti-CTLA-4 antibody, and chemoradiation therapy to increase overall response rate (ORR) and disease control rate (DCR).

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional chemotherapeutics and treatments are used for advanced and metastatic cancer, then treatment options are available, but the efficacy is limited and prognosis remains poor

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidprognosis improvement

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent combines multiple treatment modalities (chemotherapy, radiation therapy, and immunotherapy with anti-PD-L1 antibodies) into a unified treatment approach. This combination strategy addresses the limited efficacy of single-agent therapies by integrating mechanisms that complement each other, thereby improving overall therapeutic effectiveness and patient outcomes in advanced cancer treatments

Inventive Principle:

Principle #5Merging (Combining)

2Reliability

If multiple treatment modalities are combined to improve efficacy, then therapeutic response increases, but treatment complexity increases

Engineering Contradiction:

Improveoverall response rateVSAvoidtreatment regimen complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The treatment protocol is divided into distinct phases and components: chemotherapy administration, radiation therapy scheduling, and immunotherapy timing. This segmentation allows each modality to be optimized independently while maintaining overall coordination, making the complex multi-modal treatment more manageable and adaptable to individual patient needs

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS20260077040A1Compositions and methods for treating advanced solid tumors

Publication Date: 2026.03.19 ASTRAZENECA AB

AI summary

Disclosed are methods for treating solid tumors with an anti-PD-L1 antibody and an anti-CTLA-4 antibody concurrently with chemoradiation therapy (cCRT).